Claims for Patent: 10,258,619

Summary for Patent: 10,258,619

Title:	Combination therapy with glutaminase inhibitors and immuno-oncology agents
Abstract:	The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Inventor(s):	Molineaux; Susan M. (San Francisco, CA), Gross; Matthew I. (San Francisco, CA), Bromley; Susan D. (San Francisco, CA), Parlati; Francesco (San Francisco, CA), Bennett; Mark K. (Moraga, CA)
Assignee:	Calithera Biosciences, Inc. (South San Francisco, CA)
Application Number:	15/284,865
Patent Claims:	1. A method of therapeutically treating cancer, comprising conjointly administering a glutaminase inhibitor and an immuno-oncology therapeutic agent; wherein the cancer is melanoma or colon cancer; and the glutaminase inhibitor is a compound of formula (I) ##STR00013## or a pharmaceutically acceptable salt thereof, wherein: L represents CH.sub.2SCH.sub.2, CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, CH.sub.2, CH.sub.2S, SCH.sub.2, CH.sub.2NHCH.sub.2, CH.dbd.CH, or ##STR00014## wherein any hydrogen atom of a CH or CH.sub.2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH.sub.2 unit of CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2 or CH.sub.2 may be replaced by hydroxy; X, independently for each occurrence, represents S, O or CH.dbd.CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; Y, independently for each occurrence, represents H or CH.sub.2O(CO)R.sub.7; R.sub.7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, or heterocyclylalkoxy; Z represents H or R.sub.3(CO); R.sub.1 and R.sub.2 each independently represent H, alkyl, alkoxy or hydroxy; R.sub.3, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R.sub.8)(R.sub.9)(R.sub.10), N(R.sub.4)(R.sub.5) or OR.sub.6, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.4 and R.sub.5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; and R.sub.8, R.sub.9 and R.sub.10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R.sub.8 and R.sub.9 together with the carbon to which they are attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7, and wherein at least two of R.sub.8, R.sub.9, and R.sub.10 are not H. 2. The method of claim 1, wherein conjointly administering the glutaminase inhibitor and the immuno-oncology therapeutic agent provides improved efficacy relative to individual administration of the glutaminase inhibitor or immuno-oncology therapeutic agent as a single agent. 3. The method of claim 2, wherein conjointly administering the immuno-oncology therapeutic agent and glutaminase inhibitor provides an additive effect. 4. The method of claim 2, wherein conjointly administering the immuno-oncology therapeutic agent and glutaminase inhibitor provides a synergistic effect. 5. The method of claim 1, wherein the immuno-oncology therapeutic agent is an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1. 6. The method of claim 1, wherein the immuno-oncology therapeutic agent is selected from abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab, indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, MED14736, MPDL3280A, nivolumab, obinutuzumab, ocaratuzumab, ofatumumab, olatatumab, pembrolizumab, pidilizumab, rituximab, ticilimumab, samalizumab, and tremelimumab. 7. The method of claim 1, wherein L represents CH.sub.2CH.sub.2. 8. The method of claim 1, wherein Y represents H. 9. The method of claim 1, wherein X, independently for each occurrence, represents S or CH.dbd.CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl. 10. The method of claim 1, wherein Z represents R.sub.3(CO). 11. The method of claim 10, wherein each occurrence of R.sub.3 is not identical. 12. The method of claim 1, wherein R.sub.1 and R.sub.2 each represent H. 13. The method of claim 1, wherein R.sub.3, independently for each occurrence, represents substituted or unsubstituted arylalkyl, heteroarylalkyl, cycloalkyl, or heterocycloalkyl. 14. The method of claim 1, wherein the glutaminase inhibitor is a compound of formula Ia, ##STR00015## or a pharmaceutically acceptable salt thereof, wherein: L represents CH.sub.2SCH.sub.2, CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, CH.sub.2, CH.sub.2S, SCH.sub.2, CH.sub.2NHCH.sub.2, CH.dbd.CH, or ##STR00016## preferably CH.sub.2CH.sub.2, wherein any hydrogen atom of a CH or CH.sub.2 unit may be replaced by alkyl or alkoxy, any hydrogen of an NH unit may be replaced by alkyl, and any hydrogen atom of a CH.sub.2 unit of CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2 or CH.sub.2 may be replaced by hydroxy; X represents S, O or CH.dbd.CH, preferably S or CH.dbd.CH, wherein any hydrogen atom of a CH unit may be replaced by alkyl; Y, independently for each occurrence, represents H or CH.sub.2O(CO)R.sub.7; R.sub.7, independently for each occurrence, represents H or substituted or unsubstituted alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, arylalkyl, or heterocyclylalkoxy; Z represents H or R.sub.3(CO); R.sub.1 and R.sub.2 each independently represent H, alkyl, alkoxy or hydroxy, preferably H; R.sub.3 represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl or C(R.sub.8)(R.sub.9)(R.sub.10), N(R.sub.4)(R.sub.5) or OR.sub.6, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.4 and R.sub.5 each independently represent H or substituted or unsubstituted alkyl, hydroxyalkyl, acyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.6, independently for each occurrence, represents substituted or unsubstituted alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; and R.sub.8, R.sub.9 and R.sub.10 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or R.sub.8 and R.sub.9 together with the carbon to which they are attached, form a carbocyclic or heterocyclic ring system, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7, and wherein at least two of R.sub.8, R.sub.9 and R.sub.10 are not H; R.sub.11 represents substituted or unsubstituted aryl, arylalkyl, aryloxy, aryloxyalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, or C(R.sub.12)(R.sub.13)(R.sub.14), N(R.sub.4)(R.sub.14) or OR.sub.14, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7; R.sub.12 and R.sub.13 each independently represent H or substituted or unsubstituted alkyl, hydroxy, hydroxyalkyl, amino, acylamino, aminoalkyl, acylaminoalkyl, alkoxycarbonyl, alkoxycarbonylamino, alkenyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl, wherein any free hydroxyl group may be acylated to form C(O)R.sub.7, and wherein both of R.sub.12 and R.sub.13 are not H; and R.sub.14 represents substituted or unsubstituted aryl, arylalkyl, aryloxy, aryloxyalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, or heteroaryloxyalkyl. 15. The method of claim 1, wherein the glutaminase inhibitor is a compound having the structure of formula (II): ##STR00017## or a pharmaceutically acceptable salt thereof. 16. The method of claim 1, wherein the cancer is melanoma. 17. The method of claim 1, wherein the cancer is colon cancer. 18. The method of claim 1, further comprising conjointly administering one or more additional chemotherapeutic agents. 19. The method of claim 1, wherein the immuno-oncology therapeutic agent is an anti-PD-L1 antibody and the glutaminase inhibitor is a compound of formula II: ##STR00018## or a pharmaceutically acceptable salt thereof. 20. The method of claim 1, wherein the immuno-oncology therapeutic agent is an anti-PD-1 antibody and the glutaminase inhibitor is a compound of formula II: ##STR00019## or a pharmaceutically acceptable salt thereof.

Details for Patent 10,258,619

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,258,619	2035-10-05
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	10,258,619	2035-10-05
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	10,258,619	2035-10-05
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	10,258,619	2035-10-05
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	October 26, 2009	10,258,619	2035-10-05
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	April 01, 2011	10,258,619	2035-10-05
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	August 20, 2020	10,258,619	2035-10-05